Two Sigma Advisers’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.19K | Sell |
13,304
-193,428
| -94% | -$46.4K | ﹤0.01% | 2300 |
|
|
2025
Q1 | $40.7K | Buy |
206,732
+135,997
| +192% | +$26.8K | ﹤0.01% | 2331 |
|
|
2024
Q4 | $38.1K | Buy |
70,735
+58,787
| +492% | +$31.7K | ﹤0.01% | 2302 |
|
|
2024
Q3 | $11.4K | Sell |
11,948
-21,389
| -64% | -$20.3K | ﹤0.01% | 2258 |
|
|
2024
Q2 | $32.5K | Sell |
33,337
-12,800
| -28% | -$12.5K | ﹤0.01% | 2381 |
|
|
2024
Q1 | $72.9K | Sell |
46,137
-13,700
| -23% | -$21.6K | ﹤0.01% | 2325 |
|
|
2023
Q4 | $47.5K | Sell |
59,837
-4,600
| -7% | -$3.65K | ﹤0.01% | 2403 |
|
|
2023
Q3 | $50.3K | Sell |
64,437
-32,500
| -34% | -$25.4K | ﹤0.01% | 2276 |
|
|
2023
Q2 | $89.7K | Buy |
96,937
+62,937
| +185% | +$58.2K | ﹤0.01% | 2224 |
|
|
2023
Q1 | $37.1K | Buy |
34,000
+3,700
| +12% | +$4.03K | ﹤0.01% | 2477 |
|
|
2022
Q4 | $44.2K | Sell |
30,300
-800
| -3% | -$1.17K | ﹤0.01% | 2372 |
|
|
2022
Q3 | $33K | Sell |
31,100
-4,200
| -12% | -$4.46K | ﹤0.01% | 2408 |
|
|
2022
Q2 | $60K | Sell |
35,300
-69,700
| -66% | -$118K | ﹤0.01% | 2457 |
|
|
2022
Q1 | $216K | Buy |
+105,000
| New | +$216K | ﹤0.01% | 2356 |
|